scholarly journals Multitarget therapy for lupus nephritis with diffuse proliferative and membranous lesions

2008 ◽  
Vol 4 (10) ◽  
pp. 507-507
Keyword(s):  
Lupus Nephritis ◽  
Multitarget Therapy

scholarly journals Multitarget Therapy for Maintenance Treatment of Lupus Nephritis

2017 ◽  
Vol 28 (12) ◽  
pp. 3671-3678 ◽  
Author(s):  
Haitao Zhang ◽  
Zhengzhao Liu ◽  
Minlin Zhou ◽  
Zhangsuo Liu ◽  
Jianghua Chen ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Maintenance Treatment ◽  
Multitarget Therapy

scholarly journals Multitarget Therapy: An Effective and Safe Therapeutic Regimen for Lupus Nephritis

2019 ◽  
Vol 22 ◽  
pp. 365-375
Author(s):  
Tianbiao Zhou ◽  
Xialan Zhang ◽  
Wenshan Lin ◽  
Shujun Lin
Keyword(s):  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Therapy Group ◽  
Meta Analysis ◽  
Disease Activity Index ◽  
Biomedical Literature ◽  
Cochrane Library ◽  
Negative Rate ◽  
Multitarget Therapy

Introduction: We evaluated the effectiveness and safety of various multitarget therapies for inducing remission in lupus nephritis patients. Methods: Randomized controlled trials (RCT) were identified and extracted from the Embase, PubMed, Chinese Biomedical Literature Database (CBM), and the Cochrane Library until Oct 31, 2018, investigations meeting inclusion criteria were extracted, and data were analyzed by meta-analysis. The total remission (TR; complete to partial remission), complete remission (CR), albumin, proteinuria levels, negative rate of anti-double-stranded DNA antibody (ds-DNA), negative rate of anti-nuclear antibody (ANA), and systemic lupus erythematosus disease activity index (SLE-DAI) were calculated using the software of RevMan 5.3. Results: Eleven RCTs were included and analyzed. The multitarget therapy group exhibited a higher value of CR (OR=3.06, 95%CI: 2.35-3.99, P﹤0.00001) as well as TR (OR=3.83, 95%CI: 2.77-5.31, P﹤0.00001) than those in the cyclophosphamide (CYC) group. In addition, multitarget therapies had more albumin (WMD=3.50, 95%CI: 1.04-5.95, P=0.005), greater albumin increases (OR=1.96, 95%CI: 0.63-3.29, P=0.004) and higher negative rates of ds-DNA (OR=2.13, 95%CI: 1.51-3.01, P﹤0.0001) and ANA (OR=2.82, 95%CI: 1.77-4.50, P﹤0.0001) when compared with the CYC group. This group also had less proteinuria levels (WMD=-0.55, 95%CI: -0.79 to -0.30, P﹤0.0001), lower degrees of SLE-DAI (OR=-1.80, 95%CI:-2.78 to -0.81, P=0.0004), and a lower adverse reaction rate. For example, gastrointestinal syndrome, irregular menstruation and leucopenia happened less frequently in the multitarget therapy group. However, hypertension was more prevalent in the multitarget therapy group. Conclusions: Multitarget therapy is an effective and safe intervention for inducing remission in lupus nephritis patients.

scholarly journals Successful Treatment of Class V+IV Lupus Nephritis with Multitarget Therapy

2008 ◽  
Vol 19 (10) ◽  
pp. 2001-2010 ◽  
Author(s):  
Hao Bao ◽  
Zhi-Hong Liu ◽  
Hong-Lang Xie ◽  
Wei-Xin Hu ◽  
Hai-Tao Zhang ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Successful Treatment ◽  
Class V ◽  
Multitarget Therapy

scholarly journals Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis

2021 ◽  
Author(s):  
Jumpei Temmoku ◽  
Tomoyuki Asano ◽  
Kenji Saito ◽  
Haruki Matsumoto ◽  
Yuya Fujita ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Mycophenolate Mofetil ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Severe Hypoglycaemia ◽  
Insulin Receptors ◽  
Insulin Resistance Syndrome ◽  
Type B ◽  
Old Japanese ◽  
Multitarget Therapy

ABSTRACT Type B insulin resistance syndrome (TBIR) is a rare autoimmune disease characterised by autoantibodies targeting insulin receptors. TBIR is often complicated by systemic lupus erythematosus (SLE). We describe the case of a 59-year-old Japanese man with TBIR complicated with lupus nephritis (LN), who presented with nephrotic syndrome and severe hypoglycaemia. Treatment with prednisolone (PSL), mycophenolate mofetil (MMF), and tacrolimus (TAC) resulted in improved SLE activity and glucose intolerance with the reduction of anti-insulin receptor autoantibodies. To the best of our knowledge, this is the first reported case of TBIR complicated with LN that was successfully treated using multitarget therapy with PSL, MMF, and TAC.

Multitarget Therapy for Induction Treatment of Lupus Nephritis

2015 ◽  
Vol 162 (1) ◽  
pp. 18 ◽  
Author(s):  
Zhihong Liu ◽  
Haitao Zhang ◽  
Zhangsuo Liu ◽  
Changying Xing ◽  
Ping Fu ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Induction Treatment ◽  
Multitarget Therapy

scholarly journals The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis

2020 ◽  
Vol 15 (7) ◽  
pp. 1066-1072
Author(s):  
Yonatan Peleg ◽  
Andrew S. Bomback ◽  
Jai Radhakrishnan
Keyword(s):  
Mycophenolate Mofetil ◽  
Lupus Nephritis ◽  
Cell Function ◽  
Calcineurin Inhibitors ◽  
Protocol Biopsies ◽  
Attractive Option ◽  
Pregnancy And Lactation ◽  
Multitarget Therapy

The overall kidney survival among lupus nephritis patients has improved with currently used induction immunosuppression regimens of corticosteroids and either cyclophosphamide or mycophenolate mofetil; however, there still remains a significant number of lupus nephritis patients who do not achieve remission with these regimens. Investigators have looked at other immunosuppressive regimens for lupus nephritis, and there has been interest in the use of calcineurin inhibitors in this regard. Calcineurin inhibitors are potentially an attractive option because of their established ability to inhibit T cell function, attenuate proteinuria through non-immunologic means, and their safety in pregnancy and lactation. In this review, we discuss the findings and limitations of selected trials that evaluated the use of calcineurin inhibitors in the treatment of lupus nephritis, either with corticosteroids alone or as a component of multitarget therapy when combined with mycophenolate mofetil. There may be a role for calcineurin inhibitors among patients with heavy proteinuria, as well as younger patients with refractory lupus nephritis. The multitarget therapy trials reveal higher rates of remission compared with mycophenolate mofetil alone and cyclophosphamide; however, some trials highlight the possibility of more infectious adverse events. We discuss the need for further study of calcineurin inhibitors in more diverse patient populations and the need for trials with longer follow-up with “hard” endpoints beyond proteinuria reduction, such as worsening CKD or repeat protocol biopsies, given the calcineurin inhibitors ability to reduce proteinuria non-immunologically and thus increased rate of relapse when the drug is tapered. While there may indeed be a space for calcineurin inhibitors to help increase remission rates in lupus nephritis patients, more work is needed to help address the questions the studies available to date have yet to answer.

Sign in / Sign up

Export Citation Format

Share Document